Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05264727 · ClinicalTrials.gov registry record · Phase 4
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
A Phase 4 study of Healthy and Obesity, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05264727: Active Phase 4 study of Healthy and Obesity, sponsored by Mayo Clinic.
NCT05264727 is a Phase 4 study of Healthy and Obesity that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05264727, a Phase 4 study of Healthy and Obesity, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to better understand how amino acids alter the release of glucagon and insulin compared to glucose alone in health and disease.
Primary Outcome
concentration of glucose necessary to suppress glucagon by 50%
Conditions Studied
Interventions
- DRUG Dextrose
- DRUG Clinisol 15%
Study Locations (1)
Minnesota
- Mayo Clinic Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-05-30 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What the registry record for NCT05264727 still lists
NCT05264727 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Dextrose is the first listed.
NCT05264727 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05264727 about?
NCT05264727 is a clinical study titled "Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion". This study is being done to better understand how amino acids alter the release of glucagon and insulin compared to glucose alone in health and disease.
What is the current status of trial NCT05264727?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2023-05-30. Estimated completion is 2026-12-31.
What conditions does trial NCT05264727 study?
This clinical trial studies the following conditions: Healthy, Obesity, Type 2 Diabetes.
What interventions are being tested in trial NCT05264727?
The interventions under investigation include: Dextrose (DRUG), Clinisol 15% (DRUG).
Who is sponsoring clinical trial NCT05264727?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05264727 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05264727's enrollment target sits among peer trials
30 678th of 1090 higher than 363 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Acute Melatonin Supplementation on Cardiovascular Responses to Sympathetic Activation
RECRUITING · Phase 4
-
Effects of GH and Lirglutide on AgRP
RECRUITING · Phase 4
-
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
RECRUITING · Phase 4
-
Endothelial Derived Hyperpolarization Factor and Vascular Control
RECRUITING · Phase 4
-
Pharmacokinetics of Transdermal Metronidazole
ACTIVE NOT RECRUITING · Phase 4
-
VO2 Max: In Vivo Model for Functional Red Cell Testing. Can RECESS be Explained?
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI